New strategies for treating AIDS

BioEssays

Volumn 18, Issue 5, 1996, Pages 343-346

  Sandstrom, Paul A ^a   Folks, Thomas M ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; ANTIVIRUS AGENT; CORE PROTEIN; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; DRUG DESIGN; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; REVIEW; VIRUS CAPSID; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ANTIVIRAL AGENTS; CAPSID; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HIV-1; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL CORE PROTEINS; VIRUS REPLICATION; ZINC FINGERS;

EID: 0030137992     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.950180502     Document Type: Article

References (20)

1. Rice, W.G., Supko, J.G., Malspeis, L., Buckheit, R.W., Clanton, D., Bu, M., Graham, L., Schaeffer, C.A., Turpin, J.A., Domagala, J., Gogliotti, R., Bader, J.P., Halliday, S.M., Coren, L., Sowder, R.C., Arthur, L.O. and Henderson, L.E. (1995). Inhibitors of HIV-1 nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270, 1194-1197.
2. Tsai, C.-C., Follis, K.E., Sabo, A., Beck, T.W., Grant, R.F., Bischofberger, N., Benveniste, R.E. and Black, R. (1995). Prevention of SIV infection in macaques by (R)-9-(2- phospnonylmethoxypropyl)adenine. Science 270, 1197-1199.
3. Coffin, J.M. (1995). HIV-1 population dynamics in viva. Implications for genetic variation, pathogenesis and therapy. Science 267, 483-489.
4. Aldovini, A, and Young, R.A. (1990). Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J. Virol. 64, 1920-1926.
5. South, T.L., Blake, P.R., Sowder, R.C., Arthur, L.O., Henderson, L.E. and Summers, M.F. (1990). The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers. Biochemistry 29, 7786-7789.
6. Vu, X. et a. (1995). Specific disulfide formation in the oxidation of HIV-1 zinc finger protein nucleocapsid p7. Chem. Res. Toxicol. 8, 586-590.
7. Gorelick, R.J , Nigida, S.M., Bess, J.W., Arthur, L.O., Hendenon, LE. and Rein, A. (1990). Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol. 64, 3207-3211.
8. Rice, W.G. et al. (1993). Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 361, 473-475.
9. Rice, W.G. et al. (1993). The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc. Natl Acad. Sci. USA 90, 9721-9724.
10. Balzarlni, J. (1995). Anti-retroviral and pharmacological properties of 9-(2-phosphonylmethoxyethyl) adenine (PMEA). Purine and Pyrimidine Metabolism in Man, VIII (ed. A. Sahota and M.Taylor), pp. 459-464. Plentium Press, New York.
11. Kamali, F. (1993). Clinical pharmacology of ziovudine and other 2′,3′dideoxynucleoside analogues. Clin. Invest. 71, 392-405.
12. Balzarini, J. et al. (1993). Differential anti-herpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphomomethoxypropyl)-2, 6-diaminopurine. Antimicrob. Agents Chemother. 37, 332-328.
13. Franchini, G. and Reitz, Jr. M.S. (1994). Phylogenesis and genetic complexity of the nonhuman primate retroviridae. AIDS Res. Hum. Retroviruses 10, 1047-1060.
14. Tsai, C.-C. et al. (1994). Preexposure prophylaxis with 9-(2phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J. Infect. Dis. 169, 260-266.
15. Tsai, C.-C., Follis, K.E., Sabo, A., Grant, R. and Bischofberger, N. (1995) Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J. Infect. Dis. 171, 1338-1343.
16. Tsai, C.-C. et al. (1993). Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 6, 1086-1092.
17. Tokars, J.I. et al, for the CDC Cooperative Needlestick Surveillance Group (1993). Surveillance of HIV infection and zidovusine use among health care workers after occupational exposure to HIV-infected blood. Ann. Intern. Med. 118, 913-919.
18. Richman, D.D. (1993). HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 32, 149-164.
19. Richman, D.D. (1993). Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213.
20. Levantis, P. and Oxford, J.S. (1993). Molecular aspects of AZT resistance in HIV-1. Res. Virol. 143, 136-142.